Eric Halioua

Eric Halioua

Company: PDC*line Pharma

Job title: President & CEO


New Class of Antigen-Specific Cancer Active Immunotherapies Based on an Off-the-Shelf Antigen Presenting Cell Line (PDC*line) 3:00 pm

• PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells • PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors • The technology can be applied…Read more

day: Day One

Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps 10:50 am

• Exploring how companies have handled the low availability of raw materials (DNA vectors/ viral vectors) due to priority of Covid-19 for manufacturers • Assessing the best strategy to deal with the logistical manufacturing issues that have arisen due to the pandemic • Providing insight into different bio-manufacturing timelines, clinical readiness and capacity post-pandemicRead more

day: Bootcamp Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.